# JBIO — Jade Biosciences Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** JBIO  
**Sources:** 11  
**Published:** 2026-10-30  
**Canonical:** https://app.k3vl4r.com/research/deep-research-jbio-jade-biosciences-inc-catalysts-narrative-risks-6745

---

## Jade Biosciences Inc. (Nasdaq: JBIO) — Point-in-Time Assessment (as of 2026-10-30)

### Company Snapshot
Jade Biosciences is a clinical-stage biotechnology company developing monoclonal antibody therapies targeting the "upstream drivers" of autoimmune diseases, with a goal of patient-friendly, infrequent subcutaneous dosing [[10]](https://jadebiosciences.com/). Its lead programs are JADE101 (anti-APRIL, in IgA nephropathy/IgAN), JADE201 (anti-BAFF-R), and JADE301 (anti-IFN-β, in dermatomyositis) [[5]](https://www.stocktitan.net/news/JBIO/), [[9]](https://jadebiosciences.com/press-release/jade-biosciences-outlines-key-2026-objectives-and-strategy-to-advance-pipeline-of-potentially-best-in-class-monoclonal-antibodies-across-multiple-autoimmune-diseases-ahead-of-the-44th-annual-j-p-morg/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-jbio-jade-biosciences-inc-catalysts-narrative-risks-6745 (free to sign up)._
